Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Nanoparticles
3.2.1. Type of Nanoparticles
3.3. Challenges Associated with Manufacturing of Nanoparticles
3.4 Overview of Contract Manufacturing
3.4.1 Commonly Outsourced Nanoparticle Manufacturing Operations
3.5. Advantages of Outsourcing Nanoparticle Manufacturing Operations
3.6. Key Considerations while Selecting a Contract Manufacturing Partner
3.7. Future Perspective

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Nanoparticle Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Organization
4.2.5. Analysis by Type of Nanoparticle(s) Manufactured
4.2.6. Analysis by Location of Manufacturing Facilities
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Type of End User
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Quality Certifications
4.2.11. Analysis by Regulatory Organizations
4.2.12. Leading Nanoparticle Contract Manufacturers: Analysis by Number of Manufacturing Facilities

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Company Size and Type of Organization
5.3. Analysis by Company Size and Type of Nanoparticle(s) Manufactured
5.4. Analysis by Company Size and Scale of Operation
5.5. Analysis by Location of Headquarters (Country-wise)
5.6. Analysis by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Services Offered (4D Bubble Representation)
5.7. Analysis by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, Type of Service(s) Offered (Grid Representation)

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Benchmarking of Service Strength
6.5. Benchmarking of Partnership Activity
6.6. Nanoparticle Contract Manufacturers: Company Competitiveness Analysis
6.6.1. Company Competitiveness Analysis: Very Small Companies
6.6.2. Company Competitiveness Analysis: Small Companies
6.6.3. Company Competitiveness Analysis: Mid-Sized Companies
6.6.4. Company Competitiveness Analysis: Large Companies

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Ardena
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook
7.3. CordenPharma
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook
7.4. Curia
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook
7.5. Evonik
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook
7.6. LSNE Contract Manufacturing
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook
7.7. Polymun
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook
7.8. TechNanoIndia
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Nanoparticle Contract Manufacturing: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Type of Nanoparticle(s) Manufactured
8.3.5. Emerging Focus Areas
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Analysis by Geography
8.3.7.1. Region-wise Distribution
8.3.7.2. Country-wise Distribution
8.8. Concluding Remarks

9. OUTSOURCING: GO / NO-GO FRAMEWORK
9.1. Chapter Overview
9.2. Outsourcing: Go / No-Go Framework
9.3. Nanoparticle-based Therapeutics Developers Outsourcing: Go / No-Go Framework
9.3.1. Assumptions and Parameter Definitions
9.3.2. Methodology
9.3.3. Results and Interpretations
9.3.3.1. Very Small Companies

9. 3.3.2. Small Companies

9. 3.3.3. Mid-Sized Companies

9. 3.3.4. Large Companies

9. 3.3.4. Very Large Companies

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Nanoparticle Contract Manufacturing Market, 2021-2035
10.4. Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
10.4.1. Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035
10.4.2. Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035
10.4.3. Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035
10.4.4. Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035
10.5. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
10.5.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035
10.5.2. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035
10.6. Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
10.6.1. Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035
10.6.2. Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035
10.6.3. Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035
10.7. Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
10.7.1. Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035
10.7.2. Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035
10.7.3. Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035
10.7.4. Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035
10.8. Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
10.8.1. Nanoparticle Contract Manufacturing Market in North America, 2021-2035
10.8.2. Nanoparticle Contract Manufacturing Market in Europe, 2021-2035
10.8.3. Nanoparticle Contract Manufacturing Market in Asia, 2021-2035
10.8.4. Nanoparticle Contract Manufacturing Market in MENA, 2021-2035
10.8.5. Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035
10.8.6. Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035
10.9. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle and Region, 2021 and 2035
10.9.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035
10.9.2. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035
10.9.3. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035
10.9.4. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035
10.9.5. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035
10.9.6. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035
10.9.7. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035
10.9.8. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035
10.9.9. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035
10.9.10. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA, 2021-2035
10.9.11. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035
10.9.12. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035
10.10. Concluding Remarks
11. CONCLUDING REMARKS
11.1. Chapter Overview
12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. LIPOSOMA
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Asha Van Rooijen, Founder and Chief Executive Officer, Bart Metselaar, Director, Research and Development
13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION